RT Journal Article
SR Electronic
T1 A recombinant BCG-based vaccine against the human respiratory syncytial virus induces a balanced cellular immune response against viral and mycobacterial antigens
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.07.22270648
DO 10.1101/2022.02.07.22270648
A1 Pacheco, Gaspar A.
A1 Gálvez, Nicolás M. S.
A1 Andrade, Catalina A.
A1 Vázquez, Yaneisi
A1 Rodríguez-Guilarte, Linmar
A1 González, Pablo A.
A1 Bueno, Susan M.
A1 Kalergis, Alexis M.
YR 2022
UL http://medrxiv.org/content/early/2022/02/09/2022.02.07.22270648.abstract
AB BACKGROUND The human respiratory syncytial virus (hRSV) is a respiratory pathogen responsible for most cases of acute lower respiratory tract infections in infants worldwide. Although this virus represents a significant social and economic burden, there are no safe and effective available vaccines. rBCG-N-hRSV is a vaccine candidate consisting of a recombinant attenuated Mycobacterium bovis Bacillus Calmette-Guérin (BCG) expressing the nucleoprotein of hRSV (N-hRSV).METHODS rBCG-N-hRSV was applied intradermally in three different doses (5×103, 5×104, or 1×105 CFU) to healthy adults enrolled in a randomized, double-blind, dose-escalating phase 1 clinical trial (NCT03213405). Blood samples were taken before and at various time points after immunization. Cellular and humoral immune parameters were assessed by analyzing circulating immune cells and sera, respectively.RESULTS Perforin- and Granzyme B-producing PBMCs recognizing viral or mycobacterial antigens were found to increase after immunization with rBCG-N-hRSV. These cells also upregulated IFN-γ and IL-10 secretion in response to N-hRSV and upregulated IFN-γ, IL-6, and TNF-α secretion in response to mycobacterial proteins. While naïve T cell populations contracted over time, no specific memory T cell subset expanded significantly. Although binding to C1q by anti-N-hRSV or anti-mycobacterial antibodies decreased slightly after immunization, no apparent changes were found in the concentration of IgG subclasses against N-hRSV or mycobacterial antigens.CONCLUSIONS The immune response elicited by immunization with rBCG-N-hRSV consists mainly of antigen-specific T cells. The data reported here provide novel information about the characteristics of the immune response elicited after immunization with rBCG-N-hRSV, supporting the safety and immunogenicity of this vaccine.Competing Interest StatementP.A.G., S.M.B., and A.M.K. hold a patent for the rBCG-N-hRSV vaccine with Pontificia Universidad Catolica de Chile (PCT/US2008/076682).Clinical TrialNCT03213405Funding StatementThis work was supported by the Agencia Nacional de Investigacion y Desarrollo [FONDECYT grant numbers 1190830 to A.K., 21190183 to N.M.S.G., and 21210662 to C.A.P.] and by the Millenium Institute on Immunology and Immunotherapy [ANID-Millenium Science Initiative Program ICN09_016 (former P09/016F)].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee "Comite Etico CientIfico Ciencias de la Salud UC" of Pontificia Universidad Catolica de Chile, Santiago, Chile (#15126) gave ethical approval for this work. Instituto de Salud Publica de Chile (#EC819077/16) gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.